Essential-Medicine Contract-Manufacturing Transfer Director

The mandate

The incumbent contract manufacturer has repeated deviation and delivery failures across three essential oral and sterile medicines and will exit the relationship after the inventory bridge is built. Transfer plans list documents and validation batches but do not connect tacit process knowledge, analytical readiness, material sources, equipment equivalence, filing clocks, released stock and market demand. The defined problem is a supply-preserving transfer control that tells leaders when each receiving route is technically and commercially usable, not execution of validation or allocation of scarce medicine.

The deliverable is a three-product transfer book containing knowledge and document baselines, process and analytical gaps, material and component readiness, equipment and scale differences, method transfer, validation and stability gates, regulatory pathway, inventory bridge, market cutover, failure recovery and incumbent exit conditions. It includes nine critical-path cases and three end-to-end transfer simulations. Batch release, technical approval, regulatory filing, contract negotiation and production execution are excluded.

Milestone one, at month one, reconciles product, demand, stock and transfer evidence. Milestone two, at month two, closes incumbent knowledge and material gaps. Milestone three, at month four, delivers receiving-site readiness and inventory bridge. Milestone four, at month six, tests validation and filing scenarios. Milestone five, at month eight, runs three cutover simulations. Milestone six, at month nine, submits the accepted books and 180-day execution backlog.

Acceptance requires Technical Operations, Quality, Regulatory, Supply and both manufacturers to reproduce latest safe start, first potential release and market-cutover dates for all three products from controlled evidence. Each bridge must survive one failed validation batch and a three-month filing delay without double-counting incumbent output. The council accepts when nine severity-one dependencies have owners and expiry, receiving sites can run transfer control unaided and authorised functions confirm their technical and regulatory boundaries.

The client will provide product and process records, methods, deviations, equipment, material and component files, validation plans, stability, filings, batch and release history, inventory, demand, contracts and exit commitments. It will nominate incumbent and receiving-site owners, secure twelve reviews and obtain authorised decisions. Technical, Quality and Regulatory retain approval; manufacturers retain production; Procurement retains contracts; management retains market allocation and investment authority.

Why this is external work

The incumbent controls knowledge, receiving sites control their readiness and product teams protect current supply, creating incentives to report different critical paths. Internal experts also own the technical decisions the engagement must not second-guess. An independent transfer director can join the calendars and expose evidence gaps without becoming a validation approver or replacement manufacturer.

What you will own

• Reconcile three product baselines across process, method, material, equipment, validation, filing, inventory and market demand.
• Capture incumbent tacit knowledge and unresolved deviations before people, records, samples or access disappear.
• Map receiving-site gaps by scale, equipment, utilities, method, supplier, component, skill and authorised technical owner.
• Build inventory bridges using released stock, realistic incumbent yield, expiry, transfer failure and market cutover clocks.
• Run three simulations covering failed validation, delayed filing and incumbent output loss without inventing approval dates.
• Separate transfer coordination from technical approval, Quality release, regulatory filing, production and contract negotiation.
• Deliver accepted product books, critical paths, decision logs, owner training and funded 180-day execution backlog.

Candidate qualifications

• Directed complex pharmaceutical site or contract-manufacturer transfers across technical, quality, regulatory and supply workstreams.
• Has preserved patient supply when an incumbent manufacturer exited before a receiving site achieved reliable release.
• Understands process knowledge, analytical methods, materials, equipment equivalence, validation, filings and inventory bridges operationally.
• Can expose latest safe dates without assuming Technical, Quality, Regulatory, manufacturing or allocation authority.
• Has recovered missing tacit knowledge and unresolved deviation evidence from a deteriorating supplier relationship.
• Delivered transfer controls that receiving teams sustained through failed batches, filing delay and market cutover.

Non-negotiables

• Can complete twelve manufacturer, laboratory or market reviews and three simulations within nine months.
• Will not sell manufacturing capacity, validation, laboratory, regulatory, quality or sourcing services into the transfer.
• Accepts Technical, Quality, Regulatory, manufacturer, Procurement, allocation and investment decision boundaries.
• Brings completed regulated CMO transfers; programme management without product-supply accountability is insufficient.

1. 49 words maximum. Describe a medicine transfer whose inventory bridge you rebuilt after one validation failure.
2. 49 words maximum. How would you capture tacit incumbent knowledge before cooperation or access deteriorates?
3. 49 words maximum. Which transfer date should never appear before its authorised evidence owner has acted?